en · de · es · pt
bench-notes.peptides6579.com › Faq › Melanocortin Receptor Agonist Pharmacology — Evidence Review

Melanocortin Receptor Agonist Pharmacology — Evidence Review

By Editorial Desk · published 2025-09-13 · last reviewed 2025-10-10 · Faq

bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-10-10. Numbers and descriptions here follow the published literature rather than marketing material.

Melanocortin Receptor Agonist Pharmacology

Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.

Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.

Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.

Identity and Chemical Background

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.

Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.

Pt-141 at a glance

PropertyValueNotes
Molecular classCyclic heptapeptideMelanocortin receptor agonist
Molecular weightApproximately 1025 DaCalculated from the peptide sequence
AppearanceWhite to off-white powderCommon for lyophilized peptide preparations
SolubilitySoluble in waterAlso soluble in polar organic solvents
Storage temperature-20 °C or belowUsed for long-term retention

Bremelanotide Identity and Background

The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

Related pages on this site

Bremelanotide Background And Development

Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.

Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.

Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.

Chemical Identity of Bremelanotide

Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.

PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.

Peptide Handling and Storage Practice

Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.

Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.

Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.

Reference notes

This product is then treated with acryloyl chloride. The initial step in this case probably involves the acylation of nitrogen on the enamine; conjugate addition then completes the formation of the lactam ring. Treatment of that product with triethyl silane then reduces the ring unsaturation and cleaves the benzylic nitrogen bond on the auxiliary to yield as the optically pure trans isomer. Displacement of bromine with the mercapto benzthiazole completes the synthesis of izonsteride.

resigned as corporation chairman, and was replaced by childhood friend, Roger Harvin. In March 1996, Hala Moddelmog was appointed president of Church's Chicken, making her the first female president of a fast food restaurant chain.

In contrast to the open equilibrium scenario above, many swimming pools are managed by addition of sodium bicarbonate (NaHCO3) to the concentration of about 2 mmol/L as a buffer, then control of pH through use of HCl, NaHSO4, Na2CO3, NaOH or chlorine formulations that are acidic or basic. In this situation, dissolved inorganic carbon (total inorganic carbon) is far from equilibrium with atmospheric CO2. Progress towards equilibrium through outgassing of CO2 is slowed by

Sources: en.wikipedia.org

Reference notes

Changes to the curriculum of American history during the 2010s, especially in left-leaning states, have led to large numbers young Americans having a low opinion of their country and their historical figures. On the other hand, the decline of belief in American exceptionalism is a long-term trend, not unique to this cohort.

== Low gravity == It has been observed that being in Earth's orbit has an effect on the structure of spider webs in space. Spider webs were spun in low Earth orbit in 1973 aboard Skylab, involving two female European garden spiders (cross spiders) called Arabella and Anita, as part of an experiment on the Skylab 3 mission. The aim of the experiment was to test whether the two spiders would spin webs in space, and, if so, whether these webs would be the same as those that spiders produced on Earth. The experiment was a student project of Judy Miles of Lexington, Massachusetts. After the launch on July 28, 1973, and entering Skylab, the spiders were released by astronaut Owen Garriott into a box that resembled a window frame. The spiders proceeded to construct their web while a camera took photographs and examined the spiders' behavior in a zero-gravity environment. Both spiders took a long time to adapt to their weightless existence. However, after a day, Arabella spun the first web in the experimental cage, although it was initially incomplete.

== Structural studies == As of late 2007, 11 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1EJ2​, PDB: 1GZU​, PDB: 1HYB​, PDB: 1KKU​, PDB: 1KQN​, PDB: 1KQO​, PDB: 1KR2​, PDB: 1M8F​, PDB: 1M8G​, PDB: 1M8J​, and PDB: 1M8K​.

The final push for independence of Poland took place on the ground in October–November 1918. Near the end of the war, Austro-Hungarian and German units were being disarmed, and the Austrian army's collapse freed Cieszyn and Kraków at the end of October. Lviv was then contested in the Polish–Ukrainian War of 1918–1919. Ignacy Daszyński headed the first short-lived independent Polish government in Lublin from 7 November, the leftist Provisional People's Government of the Republic of Poland, proclaimed as a democracy. Germany, now defeated, was forced by the Allies to stand down its large military forces in Poland. Overtaken by the German Revolution of 1918–1919 at home, the Germans released Piłsudski from prison. He arrived in Warsaw on 10 November and was granted extensive authority by the Regency Council; Piłsudski's authority was also recognized by the Lublin government.[b1] On 22 November, he became the temporary head of state. Piłsudski was held by many in high regard, but was resented by the right-wing National Democrats. The emerging Polish state was internally divided, heavily war-damaged and economically dysfunctional.

Sources: en.wikipedia.org

Reference notes

Some unregulated transdermal progesterone products contain "wild yam extract" derived from Dioscorea villosa, but there is no evidence that the human body can convert its active ingredient (diosgenin, the plant steroid that is chemically converted to produce progesterone industrially) into progesterone.

== Chemical and biochemical features == Taurine exists as a zwitterion H3N+CH2CH2SO−3, as verified by X-ray crystallography. The sulfonic acid has a low pKa ensuring that it is fully ionized to the sulfonate at the pHs found in the intestinal tract.

This was an enormous social change, doing much to increase Conservative support amongst new homeowners and which Heseltine often cites as one of his major achievements. Heseltine noted that, "no single piece of legislation has enabled the transfer of so much capital wealth from the state to the people." He said that the 'right to buy' policy had two main objectives: to give people what they had wanted, and to reverse the trend of ever-increasing dominance of the State over the life of the individual. He said: "There is in this country a deeply ingrained desire for home ownership. The Government believe that this spirit should be fostered. It reflects the wishes of the people, ensures the wide spread of wealth through society, encourages a personal desire to improve and modernize one's own home, enables parents to accrue wealth for their children and stimulates the attitudes of independence and self-reliance that are the bedrock of a free society." Many of the homes sold were "street properties" rather than flats, which arguably helped to ghettoise the remaining council tenants on run-down inner city estates. In fact, in Crick's view, he deserves only limited credit; it had been a Conservative commitment since 1974, and much of the detailed work was done by his juniors Hugh Rossi (in opposition) and John Stanley (in government).

== Membrane biology == G protein, family of proteins involved in second messenger cascades Membrane protein, protein molecule that is attached to, or associated with, the membrane of a cell or an organelle Transmembrane protein, integral membrane protein that spans from the internal to the external surface of the biological membrane Transport protein, protein involved in the movement of a chemical across a biological membrane

It is indeed simultaneously realized that the TLC methods used thus far in almost all published studies on INMT and DMT biosynthesis are incapable to resolve DMT from those tetrahydro-β-carbolines. These findings are a blow for all previous claims of evidence of INMT activity and DMT biosynthesis in avian and mammalian brain, including in vivo, as they all relied upon use of the problematic TLC methods: their validity is doubted in replication studies that make use of improved TLC methods, and fail to evidence DMT-producing INMT activity in rat and human brain tissues. Published in 1978, the last study attempting to evidence in vivo INMT activity and DMT production in brain (rat) with TLC methods finds biotransformation of radiolabeled tryptamine into DMT to be real but "insignificant". Capability of the method used in this latter study to resolve DMT from tetrahydro-β-carbolines is questioned later. To localize INMT, a qualitative leap is accomplished with use of modern techniques of molecular biology, and of immunohistochemistry. In humans, a gene encoding INMT is determined to be located on chromosome 7. Northern blot analyses reveal INMT messenger RNA (mRNA) to be highly expressed in rabbit lung, and in human thyroid, adrenal gland, and lung. Intermediate levels of expression are found in human heart, skeletal muscle, trachea, stomach, small intestine, pancreas, testis, prostate, placenta, lymph node, and spinal cord. Low to very low levels of expression are noted in rabbit brain, and human thymus, liver, spleen, kidney, colon, ovary, and bone marrow.

Sources: en.wikipedia.org

Frequently asked questions

What is PT-141?

PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.

How does its mechanism differ from PDE5 inhibitors?

PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.

Is bremelanotide a hormone?

It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.

What is PT-141?

PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.

Network